Zacks Investment Research upgraded shares of Recro Pharma (NASDAQ:REPH) from a sell rating to a hold rating in a research note issued to investors on Wednesday, March 21st.
According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “
A number of other analysts have also recently commented on REPH. UBS started coverage on shares of Recro Pharma in a report on Tuesday, February 13th. They set an outperform rating on the stock. Oppenheimer set a $19.00 target price on shares of Recro Pharma and gave the company a buy rating in a report on Wednesday, February 28th. CIBC started coverage on shares of Recro Pharma in a report on Wednesday, February 14th. They set an outperform rating and a $19.00 target price on the stock. Finally, ValuEngine upgraded shares of Recro Pharma from a sell rating to a hold rating in a report on Thursday, March 1st. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $14.21.
Shares of NASDAQ REPH traded down $0.06 during mid-day trading on Wednesday, hitting $10.96. The stock had a trading volume of 285,539 shares, compared to its average volume of 207,192. The company has a market cap of $208.05, a price-to-earnings ratio of -5.51 and a beta of -0.74. Recro Pharma has a 1 year low of $5.81 and a 1 year high of $12.23. The company has a quick ratio of 1.55, a current ratio of 1.75 and a debt-to-equity ratio of 1.86.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.22. The business had revenue of $19.04 million for the quarter, compared to analysts’ expectations of $12.88 million. Recro Pharma had a negative net margin of 69.61% and a negative return on equity of 75.97%. equities research analysts anticipate that Recro Pharma will post -3.02 earnings per share for the current year.
In related news, major shareholder Healthcare Master Fun Broadfin sold 200,000 shares of the company’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $10.07, for a total value of $2,014,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 21.60% of the company’s stock.
A number of large investors have recently modified their holdings of the business. BlackRock Inc. raised its position in Recro Pharma by 1.4% in the 4th quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after buying an additional 13,799 shares during the last quarter. Alyeska Investment Group L.P. raised its position in Recro Pharma by 3.4% in the 3rd quarter. Alyeska Investment Group L.P. now owns 906,398 shares of the specialty pharmaceutical company’s stock worth $8,139,000 after buying an additional 29,799 shares during the last quarter. Vanguard Group Inc. raised its position in Recro Pharma by 14.2% in the 2nd quarter. Vanguard Group Inc. now owns 640,208 shares of the specialty pharmaceutical company’s stock worth $4,501,000 after buying an additional 79,520 shares during the last quarter. Lyon Street Capital LLC purchased a new position in Recro Pharma in the 4th quarter worth about $3,362,000. Finally, Cadence Capital Management LLC raised its position in Recro Pharma by 7.8% in the 4th quarter. Cadence Capital Management LLC now owns 180,715 shares of the specialty pharmaceutical company’s stock worth $1,672,000 after buying an additional 13,078 shares during the last quarter. 56.84% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This news story was reported by Macon Daily and is owned by of Macon Daily. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://macondaily.com/2018/04/12/recro-pharma-reph-raised-to-hold-at-zacks-investment-research-updated-updated-updated.html.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Get a free copy of the Zacks research report on Recro Pharma (REPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.